June 10 (Reuters) - Orion Biotechnology Canada Ltd:
* ORION BIOTECHNOLOGY ANNOUNCES RECEIPT OF PRE-IND GUIDANCE FROM THE UNITED STATES FDA ON THE FURTHER DEVELOPMENT OF OB-002O AS A POTENTIAL TREATMENT FOR SOLID TUMOURS
* ORION BIOTECHNOLOGY CANADA - FDA FEEDBACK WILL FACILITATE PREPARATION, SUBMISSION OF AN IND IN 2020 FOR OB-002O AS AN AGENT FOR TREATING SOLID TUMOURS